nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Fluorouracil—urinary bladder cancer	0.0783	0.16	CbGbCtD
Leflunomide—ABCG2—Carboplatin—urinary bladder cancer	0.0778	0.159	CbGbCtD
Leflunomide—ABCG2—Cisplatin—urinary bladder cancer	0.0665	0.136	CbGbCtD
Leflunomide—ABCG2—Etoposide—urinary bladder cancer	0.0653	0.134	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—urinary bladder cancer	0.0446	0.0912	CbGbCtD
Leflunomide—ABCG2—Methotrexate—urinary bladder cancer	0.0432	0.0883	CbGbCtD
Leflunomide—CYP1A2—Fluorouracil—urinary bladder cancer	0.0323	0.0661	CbGbCtD
Leflunomide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0291	0.0595	CbGbCtD
Leflunomide—CYP1A2—Etoposide—urinary bladder cancer	0.0269	0.0551	CbGbCtD
Leflunomide—CYP2C9—Cisplatin—urinary bladder cancer	0.0247	0.0506	CbGbCtD
Leflunomide—DHODH—prostate gland—urinary bladder cancer	0.0101	0.116	CbGeAlD
Leflunomide—PTK2B—prostate gland—urinary bladder cancer	0.00637	0.0738	CbGeAlD
Leflunomide—DHODH—female reproductive system—urinary bladder cancer	0.00549	0.0636	CbGeAlD
Leflunomide—CYP1A2—urine—urinary bladder cancer	0.00545	0.0631	CbGeAlD
Leflunomide—AHR—prostate gland—urinary bladder cancer	0.00524	0.0606	CbGeAlD
Leflunomide—CYP2C9—urine—urinary bladder cancer	0.00517	0.0599	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—urinary bladder cancer	0.00451	0.0522	CbGeAlD
Leflunomide—AHR—seminal vesicle—urinary bladder cancer	0.00443	0.0513	CbGeAlD
Leflunomide—PTK2B—renal system—urinary bladder cancer	0.00434	0.0503	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—urinary bladder cancer	0.00371	0.0429	CbGeAlD
Leflunomide—AHR—urethra—urinary bladder cancer	0.00351	0.0406	CbGeAlD
Leflunomide—PTK2B—female reproductive system—urinary bladder cancer	0.00348	0.0403	CbGeAlD
Leflunomide—DHODH—lymph node—urinary bladder cancer	0.00321	0.0372	CbGeAlD
Leflunomide—PTK2B—vagina—urinary bladder cancer	0.00314	0.0364	CbGeAlD
Leflunomide—AHR—female reproductive system—urinary bladder cancer	0.00286	0.0331	CbGeAlD
Leflunomide—AHR—vagina—urinary bladder cancer	0.00259	0.0299	CbGeAlD
Leflunomide—PTK2B—lymph node—urinary bladder cancer	0.00203	0.0236	CbGeAlD
Leflunomide—ABCG2—prostate gland—urinary bladder cancer	0.00203	0.0235	CbGeAlD
Leflunomide—ABCG2—seminal vesicle—urinary bladder cancer	0.00172	0.0199	CbGeAlD
Leflunomide—AHR—lymph node—urinary bladder cancer	0.00167	0.0194	CbGeAlD
Leflunomide—ABCG2—urethra—urinary bladder cancer	0.00136	0.0158	CbGeAlD
Leflunomide—CYP1A2—renal system—urinary bladder cancer	0.00133	0.0154	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—urinary bladder cancer	0.00133	1	CrCbGaD
Leflunomide—CYP2C9—female reproductive system—urinary bladder cancer	0.00101	0.0117	CbGeAlD
Leflunomide—ABCG2—vagina—urinary bladder cancer	0.001	0.0116	CbGeAlD
Leflunomide—ABCG2—lymph node—urinary bladder cancer	0.000649	0.00751	CbGeAlD
Leflunomide—DHODH—Metabolism—GSTT1—urinary bladder cancer	0.000253	0.00158	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000253	0.00158	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000251	0.00156	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL2—urinary bladder cancer	0.000249	0.00155	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—EP300—urinary bladder cancer	0.000248	0.00154	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000247	0.00154	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000247	0.00154	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000243	0.00152	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000243	0.00152	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00024	0.0015	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—urinary bladder cancer	0.00024	0.0015	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—HRAS—urinary bladder cancer	0.000235	0.00147	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000235	0.00146	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—urinary bladder cancer	0.000232	0.00145	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000231	0.00144	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—urinary bladder cancer	0.00023	0.00143	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000228	0.00142	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000226	0.00141	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000223	0.00139	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000223	0.00139	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00022	0.00137	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—SRC—urinary bladder cancer	0.000219	0.00136	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NQO1—urinary bladder cancer	0.000211	0.00131	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—SRC—urinary bladder cancer	0.000207	0.00129	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000206	0.00128	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PRSS3—urinary bladder cancer	0.000203	0.00127	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000202	0.00126	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000201	0.00125	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ERBB2—urinary bladder cancer	0.000199	0.00124	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000198	0.00124	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000198	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—VHL—urinary bladder cancer	0.000194	0.00121	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000192	0.0012	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—SRC—urinary bladder cancer	0.000187	0.00117	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MT2A—urinary bladder cancer	0.000182	0.00114	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000182	0.00114	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—urinary bladder cancer	0.000181	0.00113	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—urinary bladder cancer	0.00018	0.00112	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—urinary bladder cancer	0.000177	0.0011	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—urinary bladder cancer	0.000177	0.0011	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000177	0.0011	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GSTP1—urinary bladder cancer	0.000176	0.00109	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000173	0.00108	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—SRC—urinary bladder cancer	0.000173	0.00108	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—urinary bladder cancer	0.000171	0.00107	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.00017	0.00106	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.00017	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTEN—urinary bladder cancer	0.000169	0.00106	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—TYMS—urinary bladder cancer	0.000163	0.00102	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GSTM1—urinary bladder cancer	0.000161	0.00101	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NCOR1—urinary bladder cancer	0.000161	0.00101	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—SRC—urinary bladder cancer	0.000157	0.000979	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000156	0.000973	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GPX1—urinary bladder cancer	0.000155	0.000963	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—urinary bladder cancer	0.000154	0.00096	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000154	0.00096	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000154	0.000959	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—urinary bladder cancer	0.000153	0.000953	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ERCC2—urinary bladder cancer	0.000152	0.000945	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000149	0.000928	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000149	0.000926	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000147	0.000557	CcSEcCtD
Leflunomide—Pruritus—Fluorouracil—urinary bladder cancer	0.000146	0.000555	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000146	0.000554	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—urinary bladder cancer	0.000146	0.000554	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—urinary bladder cancer	0.000145	0.000906	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000144	0.000549	CcSEcCtD
Leflunomide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000144	0.000548	CcSEcCtD
Leflunomide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000144	0.000546	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—urinary bladder cancer	0.000143	0.000544	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000143	0.000543	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000143	0.000543	CcSEcCtD
Leflunomide—DHODH—Metabolism—MTHFR—urinary bladder cancer	0.000143	0.000889	CbGpPWpGaD
Leflunomide—Urticaria—Etoposide—urinary bladder cancer	0.000142	0.000541	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—urinary bladder cancer	0.000142	0.00054	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—urinary bladder cancer	0.000142	0.00054	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—urinary bladder cancer	0.000142	0.00054	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—urinary bladder cancer	0.000142	0.000539	CcSEcCtD
Leflunomide—Abdominal pain—Etoposide—urinary bladder cancer	0.000142	0.000538	CcSEcCtD
Leflunomide—Body temperature increased—Etoposide—urinary bladder cancer	0.000142	0.000538	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000142	0.000538	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000142	0.000538	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—urinary bladder cancer	0.000141	0.000537	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—urinary bladder cancer	0.000141	0.000537	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—urinary bladder cancer	0.000141	0.000537	CcSEcCtD
Leflunomide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000141	0.000536	CcSEcCtD
Leflunomide—Asthenia—Cisplatin—urinary bladder cancer	0.00014	0.000533	CcSEcCtD
Leflunomide—Pharyngitis—Epirubicin—urinary bladder cancer	0.00014	0.000533	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00014	0.000533	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00014	0.000531	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000139	0.000529	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—urinary bladder cancer	0.000139	0.000528	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000139	0.000528	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—urinary bladder cancer	0.000139	0.000527	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000138	0.000524	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—urinary bladder cancer	0.000138	0.000858	CbGpPWpGaD
Leflunomide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000137	0.000522	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000137	0.00052	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000136	0.000519	CcSEcCtD
Leflunomide—Dizziness—Fluorouracil—urinary bladder cancer	0.000136	0.000518	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000136	0.000517	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000136	0.000517	CcSEcCtD
Leflunomide—PTK2B—Immune System—BIRC3—urinary bladder cancer	0.000136	0.000846	CbGpPWpGaD
Leflunomide—Chills—Methotrexate—urinary bladder cancer	0.000136	0.000515	CcSEcCtD
Leflunomide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000134	0.000509	CcSEcCtD
Leflunomide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000134	0.000508	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—urinary bladder cancer	0.000133	0.000507	CcSEcCtD
Leflunomide—Vomiting—Gemcitabine—urinary bladder cancer	0.000133	0.000507	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000133	0.000831	CbGpPWpGaD
Leflunomide—Mental disorder—Methotrexate—urinary bladder cancer	0.000132	0.000503	CcSEcCtD
Leflunomide—Rash—Gemcitabine—urinary bladder cancer	0.000132	0.000503	CcSEcCtD
Leflunomide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000132	0.000502	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—urinary bladder cancer	0.000132	0.000502	CcSEcCtD
Leflunomide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000132	0.000502	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000132	0.00082	CbGpPWpGaD
Leflunomide—Malnutrition—Methotrexate—urinary bladder cancer	0.000132	0.0005	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000131	0.0005	CcSEcCtD
Leflunomide—Headache—Gemcitabine—urinary bladder cancer	0.000131	0.0005	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000131	0.000499	CcSEcCtD
Leflunomide—Vomiting—Fluorouracil—urinary bladder cancer	0.000131	0.000499	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000131	0.000498	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—urinary bladder cancer	0.000131	0.000497	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000131	0.000497	CcSEcCtD
Leflunomide—Rash—Fluorouracil—urinary bladder cancer	0.00013	0.000494	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—urinary bladder cancer	0.00013	0.00081	CbGpPWpGaD
Leflunomide—Dermatitis—Fluorouracil—urinary bladder cancer	0.00013	0.000494	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00013	0.000493	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.00013	0.000809	CbGpPWpGaD
Leflunomide—Headache—Fluorouracil—urinary bladder cancer	0.000129	0.000491	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000129	0.000491	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000129	0.00049	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000129	0.000489	CcSEcCtD
Leflunomide—Asthenia—Etoposide—urinary bladder cancer	0.000129	0.000489	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000129	0.000489	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000487	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000128	0.000485	CcSEcCtD
Leflunomide—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000127	0.000484	CcSEcCtD
Leflunomide—Back pain—Methotrexate—urinary bladder cancer	0.000127	0.000483	CcSEcCtD
Leflunomide—Chills—Epirubicin—urinary bladder cancer	0.000127	0.000482	CcSEcCtD
Leflunomide—Pruritus—Etoposide—urinary bladder cancer	0.000127	0.000482	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000126	0.00048	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—HDAC4—urinary bladder cancer	0.000125	0.000782	CbGpPWpGaD
Leflunomide—Alopecia—Epirubicin—urinary bladder cancer	0.000125	0.000475	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000125	0.000778	CbGpPWpGaD
Leflunomide—Nausea—Gemcitabine—urinary bladder cancer	0.000125	0.000474	CcSEcCtD
Leflunomide—Vomiting—Cisplatin—urinary bladder cancer	0.000124	0.000473	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—urinary bladder cancer	0.000124	0.000471	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—urinary bladder cancer	0.000124	0.000471	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000124	0.00047	CcSEcCtD
Leflunomide—Rash—Cisplatin—urinary bladder cancer	0.000123	0.000469	CcSEcCtD
Leflunomide—Dermatitis—Cisplatin—urinary bladder cancer	0.000123	0.000468	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—urinary bladder cancer	0.000123	0.000468	CcSEcCtD
Leflunomide—Diarrhoea—Etoposide—urinary bladder cancer	0.000123	0.000466	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000123	0.000764	CbGpPWpGaD
Leflunomide—Nausea—Fluorouracil—urinary bladder cancer	0.000123	0.000466	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000122	0.000465	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000122	0.000464	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—urinary bladder cancer	0.000122	0.000462	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000121	0.000757	CbGpPWpGaD
Leflunomide—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000121	0.000461	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000121	0.000756	CbGpPWpGaD
Leflunomide—Flatulence—Epirubicin—urinary bladder cancer	0.000121	0.000461	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000121	0.000754	CbGpPWpGaD
Leflunomide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000121	0.000458	CcSEcCtD
Leflunomide—Back pain—Epirubicin—urinary bladder cancer	0.000119	0.000452	CcSEcCtD
Leflunomide—Malaise—Methotrexate—urinary bladder cancer	0.000119	0.000451	CcSEcCtD
Leflunomide—Dizziness—Etoposide—urinary bladder cancer	0.000118	0.00045	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000118	0.00045	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000118	0.000449	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—urinary bladder cancer	0.000118	0.000449	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000118	0.000448	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—urinary bladder cancer	0.000118	0.000447	CcSEcCtD
Leflunomide—Chills—Doxorubicin—urinary bladder cancer	0.000117	0.000446	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000117	0.000444	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000117	0.000728	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—urinary bladder cancer	0.000116	0.000724	CbGpPWpGaD
Leflunomide—Nausea—Cisplatin—urinary bladder cancer	0.000116	0.000441	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—urinary bladder cancer	0.000116	0.000441	CcSEcCtD
Leflunomide—DHODH—Metabolism—PPARG—urinary bladder cancer	0.000116	0.000721	CbGpPWpGaD
Leflunomide—Alopecia—Doxorubicin—urinary bladder cancer	0.000116	0.000439	CcSEcCtD
Leflunomide—Cough—Methotrexate—urinary bladder cancer	0.000115	0.000436	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000115	0.000436	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000114	0.000434	CcSEcCtD
Leflunomide—Vomiting—Etoposide—urinary bladder cancer	0.000114	0.000433	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000114	0.000433	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—urinary bladder cancer	0.000114	0.000432	CcSEcCtD
Leflunomide—Rash—Etoposide—urinary bladder cancer	0.000113	0.000429	CcSEcCtD
Leflunomide—Dermatitis—Etoposide—urinary bladder cancer	0.000113	0.000429	CcSEcCtD
Leflunomide—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000113	0.000702	CbGpPWpGaD
Leflunomide—Headache—Etoposide—urinary bladder cancer	0.000112	0.000427	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—urinary bladder cancer	0.000112	0.000426	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—urinary bladder cancer	0.000112	0.000425	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—urinary bladder cancer	0.000112	0.000425	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—urinary bladder cancer	0.000112	0.000425	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000112	0.000424	CcSEcCtD
Leflunomide—PTK2B—Immune System—RBX1—urinary bladder cancer	0.000111	0.000694	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000111	0.000423	CcSEcCtD
Leflunomide—DHODH—Metabolism—CREBBP—urinary bladder cancer	0.000111	0.000692	CbGpPWpGaD
Leflunomide—Malaise—Epirubicin—urinary bladder cancer	0.000111	0.000422	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—urinary bladder cancer	0.000111	0.00042	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—urinary bladder cancer	0.000111	0.00042	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—urinary bladder cancer	0.000111	0.000689	CbGpPWpGaD
Leflunomide—Leukopenia—Epirubicin—urinary bladder cancer	0.00011	0.000419	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—urinary bladder cancer	0.00011	0.000419	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000109	0.000416	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—urinary bladder cancer	0.000109	0.000413	CcSEcCtD
Leflunomide—Cough—Epirubicin—urinary bladder cancer	0.000107	0.000408	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000107	0.000408	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000107	0.000408	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000107	0.000665	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000107	0.000664	CbGpPWpGaD
Leflunomide—Infection—Methotrexate—urinary bladder cancer	0.000107	0.000405	CcSEcCtD
Leflunomide—Nausea—Etoposide—urinary bladder cancer	0.000106	0.000404	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—urinary bladder cancer	0.000106	0.000404	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000106	0.000402	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000105	0.0004	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—urinary bladder cancer	0.000105	0.0004	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GLI1—urinary bladder cancer	0.000105	0.000655	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000105	0.000399	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—urinary bladder cancer	0.000105	0.000398	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—urinary bladder cancer	0.000105	0.000398	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—urinary bladder cancer	0.000105	0.000398	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—urinary bladder cancer	0.000104	0.000397	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—urinary bladder cancer	0.000104	0.000396	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000104	0.000395	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000104	0.000394	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—urinary bladder cancer	0.000104	0.000393	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000103	0.000644	CbGpPWpGaD
Leflunomide—Malaise—Doxorubicin—urinary bladder cancer	0.000103	0.00039	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—urinary bladder cancer	0.000102	0.000389	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—urinary bladder cancer	0.000102	0.000389	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—urinary bladder cancer	0.000102	0.000389	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000102	0.000387	CcSEcCtD
Leflunomide—ABCG2—Metabolism—GSTZ1—urinary bladder cancer	0.000102	0.000634	CbGpPWpGaD
Leflunomide—Palpitations—Doxorubicin—urinary bladder cancer	0.000101	0.000382	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.0001	0.000382	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—urinary bladder cancer	0.0001	0.000381	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	9.98e-05	0.000622	CbGpPWpGaD
Leflunomide—Infection—Epirubicin—urinary bladder cancer	9.98e-05	0.000379	CcSEcCtD
Leflunomide—Cough—Doxorubicin—urinary bladder cancer	9.94e-05	0.000378	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	9.89e-05	0.000616	CbGpPWpGaD
Leflunomide—Nervous system disorder—Epirubicin—urinary bladder cancer	9.85e-05	0.000374	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—urinary bladder cancer	9.83e-05	0.000374	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—urinary bladder cancer	9.83e-05	0.000374	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—urinary bladder cancer	9.8e-05	0.000373	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.78e-05	0.000372	CcSEcCtD
Leflunomide—Skin disorder—Epirubicin—urinary bladder cancer	9.76e-05	0.000371	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.71e-05	0.000369	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—urinary bladder cancer	9.71e-05	0.000369	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—urinary bladder cancer	9.69e-05	0.000368	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—urinary bladder cancer	9.69e-05	0.000368	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—urinary bladder cancer	9.69e-05	0.000368	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—urinary bladder cancer	9.66e-05	0.000367	CcSEcCtD
Leflunomide—ABCG2—Metabolism—GSTO2—urinary bladder cancer	9.65e-05	0.000601	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NAT1—urinary bladder cancer	9.65e-05	0.000601	CbGpPWpGaD
Leflunomide—Paraesthesia—Methotrexate—urinary bladder cancer	9.64e-05	0.000366	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.63e-05	0.000366	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—urinary bladder cancer	9.58e-05	0.000364	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—urinary bladder cancer	9.57e-05	0.000364	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—urinary bladder cancer	9.57e-05	0.000364	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—urinary bladder cancer	9.48e-05	0.00036	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—urinary bladder cancer	9.45e-05	0.000359	CcSEcCtD
Leflunomide—Hypotension—Epirubicin—urinary bladder cancer	9.39e-05	0.000357	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—urinary bladder cancer	9.33e-05	0.000355	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	9.33e-05	0.000581	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.29e-05	0.000353	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.27e-05	0.000352	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—urinary bladder cancer	9.25e-05	0.000352	CcSEcCtD
Leflunomide—Infection—Doxorubicin—urinary bladder cancer	9.23e-05	0.000351	CcSEcCtD
Leflunomide—Pain—Methotrexate—urinary bladder cancer	9.18e-05	0.000349	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.15e-05	0.000348	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.11e-05	0.000346	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.1e-05	0.000346	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTGS2—urinary bladder cancer	9.1e-05	0.000567	CbGpPWpGaD
Leflunomide—Insomnia—Epirubicin—urinary bladder cancer	9.08e-05	0.000345	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—urinary bladder cancer	9.07e-05	0.000345	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—urinary bladder cancer	9.03e-05	0.000343	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—urinary bladder cancer	9.02e-05	0.000343	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	9.01e-05	0.000561	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.98e-05	0.000341	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—urinary bladder cancer	8.95e-05	0.00034	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	8.87e-05	0.000553	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	8.87e-05	0.000553	CbGpPWpGaD
Leflunomide—Anorexia—Doxorubicin—urinary bladder cancer	8.86e-05	0.000337	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—urinary bladder cancer	8.84e-05	0.000336	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—urinary bladder cancer	8.84e-05	0.000336	CcSEcCtD
Leflunomide—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	8.82e-05	0.00055	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.78e-05	0.000334	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—urinary bladder cancer	8.73e-05	0.000332	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—urinary bladder cancer	8.68e-05	0.00033	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.67e-05	0.00033	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—urinary bladder cancer	8.66e-05	0.000329	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	8.63e-05	0.000538	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	8.63e-05	0.000538	CbGpPWpGaD
Leflunomide—Pain—Epirubicin—urinary bladder cancer	8.59e-05	0.000326	CcSEcCtD
Leflunomide—Constipation—Epirubicin—urinary bladder cancer	8.59e-05	0.000326	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFNA2—urinary bladder cancer	8.54e-05	0.000532	CbGpPWpGaD
Leflunomide—Urticaria—Methotrexate—urinary bladder cancer	8.53e-05	0.000324	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—urinary bladder cancer	8.48e-05	0.000322	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—urinary bladder cancer	8.48e-05	0.000322	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.47e-05	0.000322	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—urinary bladder cancer	8.41e-05	0.000319	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	8.39e-05	0.000523	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	8.39e-05	0.000523	CbGpPWpGaD
Leflunomide—Paraesthesia—Doxorubicin—urinary bladder cancer	8.35e-05	0.000317	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—urinary bladder cancer	8.29e-05	0.000315	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—urinary bladder cancer	8.28e-05	0.000315	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.28e-05	0.000516	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.21e-05	0.000312	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.2e-05	0.000511	CbGpPWpGaD
Leflunomide—Dyspepsia—Doxorubicin—urinary bladder cancer	8.18e-05	0.000311	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—urinary bladder cancer	8.08e-05	0.000307	CcSEcCtD
Leflunomide—PTK2B—Immune System—S100B—urinary bladder cancer	8.08e-05	0.000503	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.02e-05	0.000305	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—urinary bladder cancer	8.01e-05	0.000304	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—urinary bladder cancer	7.98e-05	0.000303	CcSEcCtD
Leflunomide—Pain—Doxorubicin—urinary bladder cancer	7.95e-05	0.000302	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—urinary bladder cancer	7.95e-05	0.000302	CcSEcCtD
Leflunomide—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	7.94e-05	0.000495	CbGpPWpGaD
Leflunomide—Body temperature increased—Epirubicin—urinary bladder cancer	7.94e-05	0.000302	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—urinary bladder cancer	7.94e-05	0.000302	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTEN—urinary bladder cancer	7.93e-05	0.000494	CbGpPWpGaD
Leflunomide—Hypersensitivity—Methotrexate—urinary bladder cancer	7.91e-05	0.000301	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	7.73e-05	0.000482	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	7.71e-05	0.00048	CbGpPWpGaD
Leflunomide—Asthenia—Methotrexate—urinary bladder cancer	7.7e-05	0.000293	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.7e-05	0.00048	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.66e-05	0.000291	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.6e-05	0.000474	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.6e-05	0.000289	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—urinary bladder cancer	7.59e-05	0.000289	CcSEcCtD
Leflunomide—DHODH—Metabolism—EP300—urinary bladder cancer	7.57e-05	0.000471	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	7.56e-05	0.000471	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	7.56e-05	0.000471	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	7.5e-05	0.000467	CbGpPWpGaD
Leflunomide—Hypersensitivity—Epirubicin—urinary bladder cancer	7.4e-05	0.000281	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—urinary bladder cancer	7.38e-05	0.000281	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—urinary bladder cancer	7.35e-05	0.000279	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—urinary bladder cancer	7.35e-05	0.000279	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—urinary bladder cancer	7.34e-05	0.000279	CcSEcCtD
Leflunomide—ABCG2—Metabolism—PRSS3—urinary bladder cancer	7.31e-05	0.000456	CbGpPWpGaD
Leflunomide—Asthenia—Epirubicin—urinary bladder cancer	7.21e-05	0.000274	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—RBX1—urinary bladder cancer	7.21e-05	0.000449	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	7.2e-05	0.000449	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	7.2e-05	0.000449	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	7.17e-05	0.000447	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	7.14e-05	0.000445	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	7.14e-05	0.000445	CbGpPWpGaD
Leflunomide—Pruritus—Epirubicin—urinary bladder cancer	7.11e-05	0.00027	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—urinary bladder cancer	7.1e-05	0.00027	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.07e-05	0.000441	CbGpPWpGaD
Leflunomide—Diarrhoea—Epirubicin—urinary bladder cancer	6.87e-05	0.000261	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.85e-05	0.00026	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—urinary bladder cancer	6.82e-05	0.000259	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—TSC1—urinary bladder cancer	6.77e-05	0.000422	CbGpPWpGaD
Leflunomide—Rash—Methotrexate—urinary bladder cancer	6.77e-05	0.000257	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—urinary bladder cancer	6.76e-05	0.000257	CcSEcCtD
Leflunomide—Headache—Methotrexate—urinary bladder cancer	6.72e-05	0.000256	CcSEcCtD
Leflunomide—Asthenia—Doxorubicin—urinary bladder cancer	6.67e-05	0.000253	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—urinary bladder cancer	6.64e-05	0.000252	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	6.59e-05	0.000411	CbGpPWpGaD
Leflunomide—Pruritus—Doxorubicin—urinary bladder cancer	6.58e-05	0.00025	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.5e-05	0.000405	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JAG1—urinary bladder cancer	6.45e-05	0.000402	CbGpPWpGaD
Leflunomide—Vomiting—Epirubicin—urinary bladder cancer	6.39e-05	0.000243	CcSEcCtD
Leflunomide—Nausea—Methotrexate—urinary bladder cancer	6.38e-05	0.000242	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—urinary bladder cancer	6.36e-05	0.000242	CcSEcCtD
Leflunomide—Rash—Epirubicin—urinary bladder cancer	6.33e-05	0.000241	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—urinary bladder cancer	6.33e-05	0.00024	CcSEcCtD
Leflunomide—Headache—Epirubicin—urinary bladder cancer	6.29e-05	0.000239	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—urinary bladder cancer	6.15e-05	0.000234	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	6.07e-05	0.000378	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—urinary bladder cancer	5.97e-05	0.000227	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—urinary bladder cancer	5.91e-05	0.000225	CcSEcCtD
Leflunomide—PTK2B—Immune System—FGFR3—urinary bladder cancer	5.87e-05	0.000366	CbGpPWpGaD
Leflunomide—Rash—Doxorubicin—urinary bladder cancer	5.86e-05	0.000223	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—urinary bladder cancer	5.85e-05	0.000222	CcSEcCtD
Leflunomide—ABCG2—Metabolism—TYMP—urinary bladder cancer	5.85e-05	0.000364	CbGpPWpGaD
Leflunomide—Headache—Doxorubicin—urinary bladder cancer	5.82e-05	0.000221	CcSEcCtD
Leflunomide—Nausea—Doxorubicin—urinary bladder cancer	5.52e-05	0.00021	CcSEcCtD
Leflunomide—ABCG2—Metabolism—NAT2—urinary bladder cancer	5.29e-05	0.000329	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—S100B—urinary bladder cancer	5.22e-05	0.000325	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.14e-05	0.00032	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CREBBP—urinary bladder cancer	5e-05	0.000312	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—urinary bladder cancer	4.96e-05	0.000309	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	4.87e-05	0.000304	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	4.87e-05	0.000304	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.79e-05	0.000299	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NCOR1—urinary bladder cancer	4.7e-05	0.000293	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RRM2—urinary bladder cancer	4.56e-05	0.000284	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	4.46e-05	0.000278	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	4.39e-05	0.000274	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO2—urinary bladder cancer	4.23e-05	0.000263	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HPGDS—urinary bladder cancer	4.23e-05	0.000263	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—urinary bladder cancer	4.19e-05	0.000261	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.16e-05	0.000259	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.16e-05	0.000259	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—urinary bladder cancer	4.14e-05	0.000258	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTT1—urinary bladder cancer	4.1e-05	0.000255	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.1e-05	0.000255	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.01e-05	0.00025	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.84e-05	0.000239	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.81e-05	0.000237	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGFR3—urinary bladder cancer	3.8e-05	0.000237	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—urinary bladder cancer	3.79e-05	0.000236	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.79e-05	0.000236	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.69e-05	0.00023	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ESR1—urinary bladder cancer	3.69e-05	0.00023	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—urinary bladder cancer	3.58e-05	0.000223	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—urinary bladder cancer	3.57e-05	0.000222	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.43e-05	0.000214	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NQO1—urinary bladder cancer	3.41e-05	0.000212	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—urinary bladder cancer	3.41e-05	0.000212	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SRC—urinary bladder cancer	3.31e-05	0.000206	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.24e-05	0.000202	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CREBBP—urinary bladder cancer	3.23e-05	0.000201	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1—urinary bladder cancer	3.19e-05	0.000199	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.16e-05	0.000197	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.96e-05	0.000184	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.95e-05	0.000184	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RHOA—urinary bladder cancer	2.92e-05	0.000182	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—urinary bladder cancer	2.9e-05	0.000181	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.84e-05	0.000177	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.84e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—urinary bladder cancer	2.74e-05	0.000171	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—urinary bladder cancer	2.71e-05	0.000169	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.67e-05	0.000166	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TYMS—urinary bladder cancer	2.64e-05	0.000165	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.61e-05	0.000163	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.61e-05	0.000163	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—urinary bladder cancer	2.57e-05	0.00016	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.53e-05	0.000158	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.52e-05	0.000157	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.5e-05	0.000156	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.45e-05	0.000153	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—urinary bladder cancer	2.45e-05	0.000153	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.42e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—urinary bladder cancer	2.39e-05	0.000149	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—urinary bladder cancer	2.33e-05	0.000145	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—urinary bladder cancer	2.32e-05	0.000145	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.31e-05	0.000144	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—urinary bladder cancer	2.31e-05	0.000144	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.31e-05	0.000144	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.3e-05	0.000144	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.28e-05	0.000142	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—urinary bladder cancer	2.2e-05	0.000137	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SRC—urinary bladder cancer	2.14e-05	0.000133	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.13e-05	0.000133	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.13e-05	0.000133	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.12e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.07e-05	0.000129	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.04e-05	0.000127	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.97e-05	0.000123	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—urinary bladder cancer	1.92e-05	0.00012	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—urinary bladder cancer	1.88e-05	0.000117	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.87e-05	0.000117	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.82e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.82e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.81e-05	0.000113	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.8e-05	0.000112	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—urinary bladder cancer	1.77e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.77e-05	0.00011	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.74e-05	0.000109	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.72e-05	0.000107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.67e-05	0.000104	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—urinary bladder cancer	1.58e-05	9.82e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—urinary bladder cancer	1.51e-05	9.39e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.47e-05	9.17e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.47e-05	9.16e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.46e-05	9.07e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.43e-05	8.94e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.43e-05	8.89e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.39e-05	8.65e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.33e-05	8.31e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.32e-05	8.22e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.32e-05	8.22e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.28e-05	8e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.26e-05	7.87e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.24e-05	7.75e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.24e-05	7.72e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.23e-05	7.64e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—urinary bladder cancer	1.22e-05	7.63e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.19e-05	7.39e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.17e-05	7.26e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.14e-05	7.1e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.13e-05	7.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.13e-05	7.02e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.08e-05	6.72e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.06e-05	6.6e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	9.96e-06	6.2e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	9.45e-06	5.89e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	9.08e-06	5.66e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—urinary bladder cancer	8.08e-06	5.03e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.76e-06	4.83e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	7.43e-06	4.63e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	6.48e-06	4.04e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.35e-06	3.96e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—urinary bladder cancer	6.18e-06	3.85e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.54e-06	3.45e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.28e-06	3.29e-05	CbGpPWpGaD
